One-carbon Therapeutics AB is a privately held company incorporated in Sweden
One-carbon Therapeutics AB is a privately held company incorporated in Sweden
The company focuses on the late-stage preclinical development of its lead candidate targeting MTHFD1/2 proteins, preparing submission to regulatory authorities in 2024 and starting clinical phase I trials in 2025.
Turning cutting-edge scientific discoveries into first-in-class therapies that have the potential to make dramatic improvements in the quality of life and survival of patients.
Our team has extensive experience in oncology, drug discovery, and development. We are inspired by science and committed to delivering better precision medicines to patients
Menu bar
